Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262607 · ClinicalTrials.gov registry record · Phase 2
A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
A Phase 2 study, sponsored by Clexio Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT06262607 is a Phase 2 study that has completed, run by Clexio Biosciences. The registered enrollment target is 59 participants.
The verdict
NCT06262607, a Phase 2 study, has completed, sponsored by Clexio Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).
Interventions
- DRUG Vehicle
- DRUG CLE-400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06262607
The ClinicalTrials.gov registry entry for NCT06262607 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clexio Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT06262607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06262607 about?
NCT06262607 is a clinical study titled "A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica". This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).
What is the current status of trial NCT06262607?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2024-01-29. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT06262607?
The interventions under investigation include: Vehicle (DRUG), CLE-400 (DRUG).
Who is sponsoring clinical trial NCT06262607?
This trial is sponsored by Clexio Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.